GSK Dividend Insights: Essential Information Before Aug 15, 2025 Ex-Dividend Date
Generated by AI AgentAinvest Dividend Digest
Monday, Aug 11, 2025 9:57 pm ET1min read
GSK--
Aime Summary
Aime SummaryGSK has announced a dividend of $0.428 per share, with an ex-dividend date set for Aug 15, 2025, and a payment date on Oct 9, 2025. This dividend is slightly lower than the average of the last ten dividends, which stands at $0.481. The most recent dividend was declared on Jul 10, 2025, with a payout of $0.429 per share. Both dividends are cash dividends, reflecting GSK's ongoing commitment to returning value to shareholders.
Recently, GSKGSK-- has been at the center of several pivotal developments. Notably, the company secured a substantial settlement in an mRNAMRNA-- patent dispute involving CureVacCVAC--, PfizerPFE--, and BioNTechBNTX--, netting $370 million and a 1% royalty on US sales of related vaccine products. This agreement underscores GSK's strategic position in the competitive mRNA vaccine market.
Over the past week, GSK's shares have seen a positive impact due to the US FDA's priority review for Gepotidacin. This development followed promising phase-three trial results, enhancing investor confidence in GSK's pipeline. Analysts indicated that the company is poised for growth, driven by its steady revenue expansion and strategic initiatives in pharmaceutical research and development.
Since the last update, GSK has demonstrated modest revenue growth of 1.3%, highlighting a stable, albeit slow, business expansion. This performance reflects the company's robust fundamentals, as evidenced by its financial health and strategic investments. Recent news reports emphasize GSK's focus on innovation and market adaptation, which are crucial for maintaining competitiveness in the ever-evolving healthcare industry.
In conclusion, GSK continues to make strides in both financial and strategic aspects, ensuring its position as a leader in the pharmaceutical sector. Investors should note that Aug 15, 2025, marks the last day to purchase GSK's stock and be eligible for the upcoming dividend. Any acquisitions made after this date will not qualify for this dividend payout.
Recently, GSKGSK-- has been at the center of several pivotal developments. Notably, the company secured a substantial settlement in an mRNAMRNA-- patent dispute involving CureVacCVAC--, PfizerPFE--, and BioNTechBNTX--, netting $370 million and a 1% royalty on US sales of related vaccine products. This agreement underscores GSK's strategic position in the competitive mRNA vaccine market.
Over the past week, GSK's shares have seen a positive impact due to the US FDA's priority review for Gepotidacin. This development followed promising phase-three trial results, enhancing investor confidence in GSK's pipeline. Analysts indicated that the company is poised for growth, driven by its steady revenue expansion and strategic initiatives in pharmaceutical research and development.
Since the last update, GSK has demonstrated modest revenue growth of 1.3%, highlighting a stable, albeit slow, business expansion. This performance reflects the company's robust fundamentals, as evidenced by its financial health and strategic investments. Recent news reports emphasize GSK's focus on innovation and market adaptation, which are crucial for maintaining competitiveness in the ever-evolving healthcare industry.
In conclusion, GSK continues to make strides in both financial and strategic aspects, ensuring its position as a leader in the pharmaceutical sector. Investors should note that Aug 15, 2025, marks the last day to purchase GSK's stock and be eligible for the upcoming dividend. Any acquisitions made after this date will not qualify for this dividend payout.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet